Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial

Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial

May 3, 2021 Leave a comment

 A number of energetic vaccination approaches have confirmed ineffective in lowering the substantial morbidity and mortality attributable to respiratory syncytial virus (RSV)…

Continue Reading →